[1] | LawsE. R., ParneyI. F., HuangW.,2003, Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project, Journal of Neurosurgery 2003, 99(3),467–473 |
[2] | Perry J., kamoto M.O., Guiou M., Shirai K., Errett A., Chakravarti A., 2012, Novel Therapies in Glioblastoma. Neurology Research International,1-14, doi:10.1155/2012/428565 |
[3] | Easaw J.C., Mason W. P., Perry J., Laperriere N., Eisenstat D.D., Del Maestro R., Belanger K., Fulton D., Macdonald D. for the Canadian Glioblastoma Recommendations Committee. 2011, Canadian recommendations for the treatment of recurrentor progressive glioblastoma multiforme.Current Oncology, 18(3), e126-e36 |
[4] | Anvari K. , Bahadorkhan G. , Nekooi S. , Taghizadeh A. , Kheradmand H. , Nowferesti G.,et al. 2011, Towards the Real Interdisciplinary Approach in Treating Brain Tumors: Report from the Neuro-Oncology Scientific Club opening meeting - NOSC 2011-13 October- Mashhad, IR Iran . WMC ONCOLOGY 2011;2(10):WMC002381 |
[5] | Haddad P., Zali A., Tabatabaeefar M., Nikoofar A., Hadizadeh Kharazi H., Ghadyani M., et al. 2012, Turning Interdisciplinary Brain Tumor Scienceinto Survival; Reportfrom the Neuro-Oncology Scientific Club Opening Session-NOSC 2012-19 January-Tehran, IRIran. Report and Opinion, 4(2),42-53 |
[6] | Anvari. K., Bahadorkhan G.H., Silanian-Toussi M., Rahighi S., Ghavamnasiri M.R.,Saeedi M., et al., 2012, From Fundamental Brain Tumor Science to Interdisciplinary Bedside Care; the Outcome Report from the Neuro-Oncology Scientific Club Secondmeet-up (NOSC-2), 19th April 2012, Mashhad, Iran. International Journal of Medical and Clinical Research, 3(5), 168-175 |
[7] | Torabi Nami M., Hejazi Farahmand S., Mohammadzadeh F., 2012, Neuro-Oncology Scientific Club and the Iranian Brain Tumor Registry. European Association of Neuro-Oncology. Neuro-Oncology, 14(3), iii 1-iii94 |
[8] | Brem S.S., Bierman P.J., Brem H., Butowski N., Chamberlain M.C., Chiocca E.A., De AngelisL.M.,et al., 2011, National Comprehensive Cancer Network.J NatlComprCanc Netw, 9(4),352-400 |
[9] | Stupp R., Tonn J.C., Brada M., Pentheroudakis G., et al. 2010, High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol, 21 (5),v190-v193 |
[10] | Van Meir E. G., Hadjipanayis C. G., Norden, A. D., Shu, H. K., Wen, P. Y., Olson, J. J., 2010, Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA: A Cancer Journal for Clinicians, 60 (3), 166–93 |
[11] | SanaiN., BergerM.S., 2008,Gliomaextentof resection and its impact on patient outcome. Neurosurgery, 62(4),753-64 |
[12] | Miriman off R.O., Gorlia T., Mason W., Van den Bent M.J., Kortmann R.D., Fisher B., etal. 2006, Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCICCE3 Phase IIIR and omized Trial. Journal of Clinical Oncology, 24(16), 2563-2569. |
[13] | ParavatiA.J.,HeronD.E.,LandsitteD.,FlickingerJ.C. 2011, Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validationof Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. JNeurooncol, 104, 339–349 |
[14] | GilbertM.R., 2006, NewTreatmentsforMalignant Gliomas: Careful Evaluation and Cautious Optimism Required. Annals of Internal Medicine, 144(5), 371-373 |
[15] | Albright R.E., Brenemman J.C., Warnick R.J., 2008, Safetyand efficacy of permanent iodine-125 seed implantsand carmustine wafers in patients withrecurrentglioblastomamultiforme. J.Neurosur, 108(2), 236-42 |
[16] | Brennan C.W., 2007, Functional image guided neurosurgery. Functional Neuroimaging, A Clinical Approach. First edition, Informa healthcare,91-107. |
[17] | Spena G., Nava A., Cassini F., Pepoli A., Bruno M., D'Agata F., et al., 2010, Preoperative and intraoperative brain mapping for the resection of eloquent-area tumors. A prospective analysis of methodology, correlation, and usefulness based on clinical outcomes. ActaNeurochir.,152(11), 1835-1846. |
[18] | Kristiansen K., Hagen S., Kollevold T., Torvik A.,, Holme I., Nesbakken R., 1981, Combined modality therapy of operatedastrocytomas grade I, II and IV. Confirmation of the value of postoperative irradiation and lack of potentiation ofbleomycin on survival time: a prospective multicenter trial of the scandinavian glioblastoma study group,Cancer , 47(4), 649–652 |
[19] | Stupp R., Mason W.P.,van denBent M.J. et al., 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, New England Journal of Medicine , 352(10), 987–996 |
[20] | Stupp R.,HegiM.E., MasonW. P., etal., 2009,Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy a lone on survival in glioblastoma in arandomized phase I II study : 5-year analysis of the EORTC -NCIC trial,” The Lancet Oncology, 10(5), 459–466 |
[21] | EstellerM., Garcia-FoncillasJ., AndionE., et al. 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, New England Journal of Medicine , 343(19), 1350–1354 |
[22] | HegiM. E., DiserensA. C., GodardS., et al., 2004, Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide, Clinical Cancer Research, 10(6), 1871–1874 |
[23] | Souhami L., Seiferheld W., Brachman D.et al., 2004, Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmuttine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol, International Jour n al of Radiation Oncology Biology Physics , 60(3), 853–860 |
[24] | LaperriereN. J., Leung P. M. K., McKenzie S., et al. 1998, Randomized study of brachy therapy in the initial management of patients with malignant astrocytoma, International Journalof Radiation Oncology Biology Physics , 41(5), 1005–1011 |
[25] | GilbertM. R., Wang M., Aldape K.D., et al.,2011, RTOG 0525:a randomize d phase III trial comparing standard adjuvanttemozolomide (TMZ) with a dose-dense (dd) schedule innewly diagnosed glioblastoma (GBM), Journal of Clinical Oncology, 29(15), 1935 - 2127 |
[26] | HottingerA. F., Homicsko K., Negretti L., Lhermitte B.,Stupp R., 2012, Decision making and management of gliomas: practicalconsiderations, Annals of Oncology 23(10), 33 –40 |
[27] | Johnson D.R., Chang S.M., 2012, Recent Medical Management of Glioblastoma, Advances in Experimental Medicine and Biology, 746, 26-40 |
[28] | Chamberlain M.C., 2011, Bevacizumab for the Treatment of Recurrent Glioblastoma. Clin Med Insights Oncol, 5, 117–129 |
[29] | Xu T., Chen J., Lu Y.,Wolff J.E., 2010,Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis, BMC Cancer, 10,252, doi: 10.1186/1471-2407-10-252 |
[30] | TEMODAL®[package insert]. Herts, UK: Merck Sharp &Dohme Limited; 2011 |
[31] | Fogh S. E., Andrews D.W., Glass J., et al., 2010, Hypofractionated stereotactic radiation therapy : an effective therapy for recurrent high grade gliomas, Journal of Clinical Oncology, 28(18), 3048–3053 |
[32] | Gunjur A., Lau E., Taouk Y., Ryan A., 2011, Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: Aretrospective analysis. Journal of Medical Imaging and Radiation Oncology, 55,603–610 |
[33] | Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M.J., 2008, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas, Lancet Oncol, 9, 453–61 |
[34] | Kang H.C.,Kim C.Y., Han J.H., Choe G.Y.,Kim J.H., Kim I.A.,2010, Pseudoprogression in patients with malignant gliomastreated with concurrent temozolomide and radiotherapy: potential role of p53, J Neuroonco, doi: 10.1007/s11060-010-0305-7 |
[35] | Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G.,Galanis E., et al., 2010,Updated Response Assessment Criteria for High-GradeGliomas: Response Assessment in Neuro-OncologyWorking Group, J ClinOncol, 28, 1963-1972 |